BidaskClub lowered shares of K2M Group (NASDAQ:KTWO) from a buy rating to a hold rating in a research report released on Wednesday morning.
A number of other analysts have also recently weighed in on KTWO. Cowen set a $28.00 price objective on shares of K2M Group and gave the stock a buy rating in a report on Thursday, August 17th. William Blair reaffirmed an outperform rating on shares of K2M Group in a report on Tuesday, October 10th. Piper Jaffray Companies reaffirmed an overweight rating and issued a $28.00 price objective on shares of K2M Group in a report on Tuesday, October 10th. Oppenheimer set a $24.00 price objective on shares of K2M Group and gave the stock a buy rating in a report on Wednesday, October 18th. Finally, JMP Securities reaffirmed an outperform rating and issued a $25.00 price objective (down previously from $30.00) on shares of K2M Group in a report on Tuesday, October 10th. One research analyst has rated the stock with a sell rating, two have given a hold rating and ten have issued a buy rating to the stock. The stock has a consensus rating of Buy and a consensus price target of $24.40.
Shares of K2M Group (NASDAQ:KTWO) opened at $17.19 on Wednesday. The company has a debt-to-equity ratio of 0.29, a quick ratio of 1.67 and a current ratio of 3.06. K2M Group has a twelve month low of $16.44 and a twelve month high of $25.99.
K2M Group (NASDAQ:KTWO) last released its quarterly earnings data on Wednesday, November 1st. The medical device company reported ($0.20) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.19) by ($0.01). K2M Group had a negative return on equity of 16.02% and a negative net margin of 16.22%. The firm had revenue of $62.65 million during the quarter, compared to analyst estimates of $62.69 million. During the same period last year, the business earned ($0.19) EPS. The firm’s revenue was up 5.6% on a year-over-year basis. analysts forecast that K2M Group will post -0.86 EPS for the current year.
A number of institutional investors and hedge funds have recently made changes to their positions in KTWO. Cubist Systematic Strategies LLC grew its position in K2M Group by 7,765.0% in the 3rd quarter. Cubist Systematic Strategies LLC now owns 4,719 shares of the medical device company’s stock valued at $100,000 after buying an additional 4,659 shares in the last quarter. Rockefeller Financial Services Inc. bought a new position in K2M Group in the 3rd quarter valued at about $105,000. BNP Paribas Arbitrage SA grew its position in K2M Group by 5,175.3% in the 2nd quarter. BNP Paribas Arbitrage SA now owns 4,484 shares of the medical device company’s stock valued at $109,000 after buying an additional 4,399 shares in the last quarter. Legal & General Group Plc grew its position in K2M Group by 9.1% in the 1st quarter. Legal & General Group Plc now owns 6,763 shares of the medical device company’s stock valued at $138,000 after buying an additional 564 shares in the last quarter. Finally, Dorsey & Whitney Trust CO LLC bought a new position in K2M Group in the 2nd quarter valued at about $211,000. Hedge funds and other institutional investors own 99.16% of the company’s stock.
K2M Group Company Profile
K2M Group Holdings, Inc is a medical device company focused on designing, developing and commercializing spine and minimally invasive technologies and techniques. The Company’s solutions are focused on achieving three-dimensional Total Body Balance. Its spine products are used by spine surgeons to treat spinal pathologies, such as deformity (primarily scoliosis), trauma and tumor.
Receive News & Ratings for K2M Group Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for K2M Group Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.